Insulin analogues and cancer risk: The emergence of second-generation studies

Diabetologia

Volumn 55, Issue 1, 2012, Pages 7-9

  Renehan, A G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer risk; Diabetes; Glucose lowering drugs; Insulin analogue; Pharmaco epidemiology

Indexed keywords

HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; INSULIN, REGULAR, HUMAN; MALE; NEOPLASMS;

EID: 84856755161     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2352-9     Document Type: Review

References (12)

1. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765, Erratum 52: 2469
2. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
3. Currie CJ, Poole CD, Gale EA (2009) The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
4. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
5. Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708
6. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511-513
7. Carstensen B (2010) Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 59:1254-1260. doi:10.2337/db10-0777, Diabetes 59: e17-18
8. Renehan A, Smith U, Kirkman MS (2010) Linking diabetes and cancer: a consensus on its complexity [commentary]. Lancet 375:2201-2202
9. Ruiter R, Visser LE, van Herk-Sukel MPP et al (2011) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. doi:10.1007/s00125-011-2312-4
10. Johnson JA, Bowker SL, Richardson K, Marra CA (2011) Timevarying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54:2263-2271
11. Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M (2011) Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54:2254-2262
12. Renehan AG, Soerjomataram I, Leitzmann MF (2010) Interpreting the epidemiological evidence linking obesity and cancer: a framework for population-attributable risk estimations in Europe. Eur J Cancer 46:2581-2592